Leg ulcers in elderly on hydroxyurea: A single center experience in ph-myeloproliferative disorders and review of literature

Aging Clinical and Experimental Research

Volumn 18, Issue 3, 2006, Pages 187-190

  Ruzzon, Elisabetta ^a   Randi, Maria Luigia ^a   Tezza, Fabiana ^a   Luzzatto, Guido ^a   Scandellari, Raffaella ^a   Fabris, Fabrizio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Essential thrombocythemia; Hydroxyurea; Leg ulcers; Myeloproliferative disorders; Polycythemia vera

Indexed keywords

HYDROXYUREA;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; EXPERIENCE; FEMALE; HUMAN; LEG ULCER; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POLYCYTHEMIA VERA; THROMBOCYTHEMIA;

EID: 33746140550     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324647     Document Type: Article

References (29)

1. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19 (Suppl 9): 1-10.
2. Murphy S. Therapeutic dilemmas: balancing the risk of bleeding, thrombosis and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemost 1997; 78: 622-6.
3. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132-6.
4. Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica, 2005; 90: 261-2.
5. Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea, therapy. Arch Dermatol 1975; 111: 183-7.
6. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975; 12: 339-51.
7. Murphy S, Iland H, Rosenthal D, Laszlo, J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 1986; 23: 177-82.
8. Vassallo C, Passamonti F, Merante S, et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol 2001; 26: 141-8.
9. Hirri HM, Green PJ. Skin lesion caused by hydroxyurea. Eur J Haematol 2001; 67: 328-9.
10. Chaine B, Neonato MG, Girot R, Aractingi S. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol 2001; 137: 467-70.
11. Sirieix ME, Debure C, Baudot N, et al. Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol 1999; 135: 818-20.
12. Poros A, Nadasdy K. Leg ulcer in hydroxyurea-treated patients. Haematologia (Budap) 2000; 30: 313-8.
13. Olesen LH, Pedersen BB. Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders. Ugeskr Laeger 2001; 163: 6908-11.
14. Nguyen TV, Margolis DJ. Hydroxyurea and lower leg ulcers. Cutis 1993; 52: 217-9.
15. Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998; 128: 29-32.
16. Disla E, D'Eamour L, Cioriou M. Hydroxyurea-associated leg ulceration. Ann Intern Med 1998; 129: 252-3.
17. Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol 1998; 39: 372-4.
18. Ravandi-Kashani F, Cortes J, Cohen P, et al. Cutaneous ulcers associated with hydroxyurea therapy in myeloproferative disorders. Leuk Lymphoma 1999; 35: 109-18.
19. Vèlez A, Garcìa-Aranda JM, Moreno JC. Hydroxyurea-induced leg ulcers: is macroerythrocytosis a pathogenic factor? J Eur Acad Dermatol Venereol 1999; 12: 243-4.
20. Bader U, Banyai M, Boni R, Burg G, Hafner J. Leg ulcers in patients with myeloproliferative disorders: disease or treatment-related? Dermatology 2000; 200: 45-8.
21. Yeh H, Lichtman SM. Hydroxyurea-induced cutaneous ulceration in older patients. J Am Geriatr Soc 2000; 48: 232.
22. Natarajan S, Williamson D, Grey J, Harding KG, Cooper RA. Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey. J Dermatol Treat 2001; 12: 33-6.
23. Young HS, Kirby B, Steward JC. Aggressive, extensive, vasculitic leg ulceration associated with hydroxyurea therapy and a fatal outcome. Clin Exp Dermatol 2001; 26: 664-7.
24. Demircay Z, Comert A, Adiguzel C. Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia. Int J Dermatol 2002; 41: 872-4.
25. Sastre JL, Bravo A, Tembràs S, Gomez R, Ulibarrena C. Leg ulcers associated with hydroxyurea therapy. Haematologica 2003; 88 EIM01.
26. Montefusco E, Alimena G, Gastaldi R, Carlesimo OA, Valesini G, Mandelli F. Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia. Tumori 1986; 72: 317-21.
27. Kido M, Tago O, Fujiwara H, Ito M, Niwano H. Leg ulcer associated with hydroxyurea treatment in a patient with chronic myelogenous leukaemia: successful treatment with prostaglandin E1 and pentoxifylline. Br J Dermatol 1998; 139: 1124-6.
28. Stagno F, Guglielmo, P, Consoli U, Fiumara P, Russo M, Giustolisi R. Successful healing of hydroxyurea-related leg ulcers with topical granulocyte-macrophage colony-stimulating factor. Blood 1999; 94: 1479-80.
29. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Haematology, the Italian Society of Experimental Haematology and the Italian Group for bone marrow transplantation. Haematologica 2004; 89: 215-32.